For sponsors and biotechs, momentum is everything but data privacy gaps have a way of surfacing at the worst possible moment in extremely costly ways. This session walks through three checkpoints where privacy oversights can bring progress to a halt: regulatory submission, site-level execution, and the eventual sale or licensing of trial IP.
- Submission: the privacy documentation and registration gaps that can delay or derail regulatory filings
- Site: where data protection responsibilities between sponsor, CRO and site most often break down
- Sale: why buyers and licensing partners are scrutinising data provenance and privacy compliance more closely, and how gaps can devalue or derail a deal
Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple prizes or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!
- Effectively championing adaptive trial designs to stay nimble as the clinical research landscape continues to evolve
- Streamlining protocol finalization, regulatory submissions, and feasibility assessments to shorten start-up timelines
- Identifying and engaging the right sites as part of a broader operational readiness strategy
- Coordinating cross-functional teams, vendor partnerships, and internal stakeholders to ensure smooth study initiation
- Implementing robust onboarding, training, and communication plans to set the trial up for success from day one
- Reducing contract cycle times to accelerate study start-up
Moderator: Michael Murphy, Director, Legal & Associate General Counsel, Ionis
With drinks and refreshments, interactive breakout sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will run twice and be led by a table moderator and will focus on a different challenge within clinical trials. Breakout discussions are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.
| Discussion 1 |
Turning Inspection Fears into Operational Readiness In An Uncertain Regulatory Environment
Hosted by Regina Griffin, Associate Director, Clinical Operations, Autobahn Therapeutics |
| Discussion 2 |
Vendor Oversight – Whose Job Is It Anyways?
Hosted by Denise Deegan, Associate Director, Clinical Operations, Pionyr Immunotherapeutics |
| Discussion 3 |
Beyond the Pilot: Turning AI into a Scalable Drug Development Strategy
Hosted by Shivam Patel, Monitoring Oversight and AI Automation Lead, Moderna |
| Discussion 4 |
Breaking Down Data Silos: Creating a More Connected Clinical Trial Ecosystem
Hosted by Wei Cheng, Executive Director, Apogee Therapeutics |
| Discussion 5 |
Why Patients Walk Away from Clinical Trials and What the Industry Still Gets Wrong |